chronic%20myeloid%20leukemia
CHRONIC MYELOID LEUKEMIA

Chronic myelogenous leukemia (CML) is a malignant myeloid disorder characterized by the presence of a distinctive cytogenetic abnormality known as the Philadelphia chromosome.

Exposure to ionizing radiation is the only known risk factor with median presentation at age >50 years old.

Three phases of the disorder are chronic, accelerated and blast.

Choice of therapy is influenced by age, availability of a donor, comorbidities and phase of CML.

Drug Information

Indication: Alone or in combination w/ other chemotherapeutic agents for induction of leukaemia remission, particularly fo...

Indication: In combination w/ cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell...

Indication: Induction & maintenance of remissions in acute myelocytic leukemia in adult & childn. Other leukemias ...

Indication: Alone or in combination w/ other chemotherapeutic agents for induction of remission of acute myeloid leukaemia...

Indication: Chronic granulocytic leukaemia. Prolongs remission in polycythaemia vera, particularly in cases w/ marked thro...

1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 07 May 2019

Combination therapy with the MET inhibitor savolitinib and the EGFR inhibitor osimertinib showed robust and durable clinical responses among patients with EGFR-mutated and MET-amplified non-small-cell lung cancer (NSCLC), according to results of the phase Ib TATTON study presented at AACR 2019.

Roshini Claire Anthony, 6 days ago

Omitting first-line chemotherapy for patients with metastatic HER2+ breast cancer treated with pertuzumab plus trastuzumab did not affect overall survival (OS) despite shorter progression-free survival (PFS), according to updated results of the phase II PERNETTA* trial.